Lung Cancer News

New global cancer diagnoses could reach 35 million by the year 2050, according to a report from the American Cancer Society published in CA: A Cancer Journal for Clinicians.

Patients with multimorbidity and limited life expectancy are often unaware of the risks of lung cancer screening, and clinicians might be hesitant to discuss it, according to a pair of studies published in the Annals of Family Medicine.

Adagrasib monotherapy improved PFS and overall response rate among adults with pretreated locally advanced or metastatic non-small cell lung cancer harboring a KRASG12C

Surgeons at Northwestern Medicine Canning Thoracic Institute have performed what is believed to be the first-ever combined lung-liver transplant for a patient with advanced lung cancer, according to medical staff at Northwestern Medicine.

Clinicians treating patients with tumor-infiltrating lymphocytes should closely monitor toxicities associated with interleukin-2 and halt administration of the drug if necessary, according to the first guidelines regarding the therapy.

The combination of pembrolizumab and maintenance olaparib failed to significantly improve survival outcomes among adults with metastatic nonsquamous non-small cell lung cancer, according to the agent’s manufacturer.

Most of the major cancer clinical trial centers in the U.S. are located near more affluent and white populations compared with the national average, according to results published in JAMA Oncology.

In this episode, host Shikha Jain, MD, speaks with Barnaby Balmforth, PhD, about the evolution of genomics in cancer care, the impact of personalized care tools and more.

Patients with positive lung cancer screening findings frequently delay their first follow-up visit, according to results published in Annals of the American Thoracic Society.

In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more.